7:30 am Registration & Coffee
8:25 am Chair’s Opening Remarks
CD73/CD39 Understanding Biological Principles & Concepts to Enable Fast Development
8:30 am Targeting CD39-Adenosine Pathway for Immuno-Oncology
Synopsis
- Why CD39 is an excellent target for cancer immune-oncology
- Preclinical characterization of eurestobart (ES002), Elpiscience’s anti-CD39 antibody
- Effect of ES014, a first-in-class bi-specific antibody targeting CD39 and TGF-beta, in modulating the immune system in the tumor microenvironment (TME)
9:00 am Clinical and translational perspectives on αCD73 in Non-Small Cell Lung Cancer
Synopsis
- Understanding key learnings from the preclinical stage that informed patient selection strategy
- Examining the benefits and drawbacks of focusing on CD73 in the adenosine pathway
9:30 am Cidara Drug-Fc-Conjugates (Dfcs): A New Approach To Treatment Of Cancer
Synopsis
- Cidara has developed a Drug-Fc-Conjugate (DFC) platform and is using it to advance candidates against several immuno-oncology targets.
- We are advancing a development candidate DFC, CD421, that targets CD73.
- The emerging CD421 preclinical data package highlights its potential for differentiation from existing small molecule and monoclonal antibody therapies in clinical trials. CD421 combines the best attributes of small molecule and monoclonal antibody therapies
10:00 am Morning Break & Networking
10:30 am Improving Outcomes for People With Cancer By Developing TTX-030, A First- In-Class, Anti-CD39 Antibody
Synopsis
- Explore translational practices and how they can be improved for greater confidence upon reaching the clinic
- Using novel approaches to inform clinical decision making
11:00 am Panel Discussion – Barriers to Development of CD73/CD39 Mono and Combo Therapies and Potential Solutions
Synopsis
- Compare and contrast single vs dual inhibition of adenosine enzymes
- Explore current challenges with identifying and validating predictive biomarkers of response
- Suggest methods and technologies worth pursuing to better select patients for trials
12:00 pm Lunch & Networking
Exploring Adenosine Receptor Biology & Taking Advantage of its Strengths
1:00 pm Beyond the T cell: Exploring the Importance of the Humoral Immune System in Adenosine Immunosuppression
Synopsis
- Expression of A2AR on human B cells
- Function of A2AR on human B cells
- Clinical correlation in patients treated with inupadenant
1:30 pm Next Generation Adenosine Therapeutics for A2B
Synopsis
- Explain the biological importance of A2B
- Discuss the development route for A2B therapeutics and current challenges/opportunities
2:00 pm Targeting Adenosine Pathway With Antagonizing Anti-A2A\zr Antibody to Enhance Anti-Tumor Immunity
Synopsis
- Discuss current molecules targeting adenosine receptors in preclinic and clinics
- Show the discovery of an antagonizing anti-A2aR antibody to enhance anti-tumor immunity
2:30 pm Panel Discussion – Preclinical and Clinical Adenosine Receptor Targeting
Synopsis
- Discuss therapeutic and strategic strengths of single receptor targeting vs dual inhibition
- Examine which aspects of A2AR and A2BR make it a better or worse target than CD73/39